Urothelial cancer and other urogenital organs using N- (4- (6,7-dimethoxyquinolin-4-yloxy) phenyl) -N ′-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide Treatment for malignant tumor

摘要

The present disclosure relates to a method for treating urothelial cancer using cabozantinib which is a kinase inhibitor. The present disclosure used a kinase inhibitor N- (4- (6,7-dimethoxyquinolin-4-yloxy) phenyl) -N ′-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide. The present invention relates to a method for treating cancers including urothelial cancer in human patients and other genitourinary malignant tumors. In one aspect, the present invention relates to a method for treating urothelial cancer in a human patient, the method comprising administering to the human patient a therapeutically effective amount of cabozantinib or a pharmaceutically acceptable salt thereof, alone or in combination. Including administration in combination with multiple therapeutic agents. [Selection figure] None